Nara Organics Faces Lawsuit Over Infant Formula Botulism Concerns Raises Alarm About Food Safety
In a troubling development for food safety in the U.S., Marler Clark, the prominent Food Safety Law Firm, has initiated legal proceedings against Nara Organics. The suit comes on behalf of an infant who was hospitalized with botulism following the consumption of the company's Whole Milk Organic Powdered Infant Formula.
On June 13, 2026, Nara Organics issued a widespread recall of its infant formula after federal and state health officials connected it to a multistate outbreak of infant botulism. Reports revealed that three infants in California, Pennsylvania, and Washington had fallen ill with the type A botulinum toxin between April and May 2026. These infants, who were just two to five months old, required hospitalization and treatment with BabyBIG®, an antitoxin manufactured by California's Department of Public Health.
The recalled formula, crafted in Germany and exclusively sold across the U.S. in Target stores and online platforms, had been available between July 2025 and June 2026. This alarming incident marks the second outbreak of infant formula-induced botulism in a mere seven months. In November 2025, another whole milk-based formula was linked to a similar outbreak, which resulted in approximately 48 infants falling ill across 17 states.
The current lawsuit emphasizes that the risks associated with this specific ingredient, whole milk powder, were well-documented prior to the outbreak. In fact, back on March 8, 2023, the FDA made a Clear Call-to-Action to infant formula producers, explicitly recognizing Clostridium botulinum as a concern, particularly in the use of whole milk powder. Despite these warnings, Nara Organiсs continued to market its product, showcasing the high whole milk fat content as a selling point, while failing to adequately notify parents about the potential dangers.
The central allegation in the lawsuit is that Nara Organics transformed its potentially hazardous high milk-powder content into a marketing strategy, presenting it as an attribute of premium quality, without any cautionary notes to consumers. After the outbreak, the company characterized its recall as a precautionary measure, carefully crafting its messaging to imply it was acting out of diligence rather than acknowledging its product's role in harming infants.
“Every company selling whole-milk-powder formula — including Nara — was explicitly warned about the contamination risk by spring 2026,” said Bill Marler, managing partner at Marler Clark. He highlighted that the company's messaging did not align with the known dangers, as they promoted their product as the safest on the market and failed to disclose the outlined risks.
The plaintiffs, Erica and Micky Goldfin, filed their lawsuit in the U.S. District Court for the Eastern District of Pennsylvania. Their son, identified in the case as W.G., exhibited clear signs of infant botulism just two months after starting on the formula. Initially showing symptoms typical of the illness, W.G. was treated at Children's Hospital of Philadelphia, where he spent crucial time under intensive care. While he has shown improvements, he continues to receive support for delays in development as a result of the illness.
In light of the recent events, Bill Marler has responded with a call for Congress to pass the Infant Formula Safety Modernization Act, a bipartisan initiative introduced in March 2026. This proposed legislation would require infant formula manufacturers to engage in testing for Clostridium botulinum for the first time. Marler emphasized that such reforms could prevent further tragedies.
“This is a concrete step that could have averted this disaster. We must act now to ensure the safety of our children's food,” he urged.
The ongoing tragedy surrounding Nara Organics represents a lapse in accountability within the food industry and raises pressing concerns about the safety regulations governing infant feeding products. As investigations continue, the implications of this lawsuit serve as a stark reminder of the need for transparency and rigorous testing within the market. Parents trust manufacturers to provide safe products for their children, and cases like this highlight the urgent necessity for reform and more stringent oversight of food safety practices nationwide.
The Outbreak
On June 13, 2026, Nara Organics issued a widespread recall of its infant formula after federal and state health officials connected it to a multistate outbreak of infant botulism. Reports revealed that three infants in California, Pennsylvania, and Washington had fallen ill with the type A botulinum toxin between April and May 2026. These infants, who were just two to five months old, required hospitalization and treatment with BabyBIG®, an antitoxin manufactured by California's Department of Public Health.
The recalled formula, crafted in Germany and exclusively sold across the U.S. in Target stores and online platforms, had been available between July 2025 and June 2026. This alarming incident marks the second outbreak of infant formula-induced botulism in a mere seven months. In November 2025, another whole milk-based formula was linked to a similar outbreak, which resulted in approximately 48 infants falling ill across 17 states.
Known Risks
The current lawsuit emphasizes that the risks associated with this specific ingredient, whole milk powder, were well-documented prior to the outbreak. In fact, back on March 8, 2023, the FDA made a Clear Call-to-Action to infant formula producers, explicitly recognizing Clostridium botulinum as a concern, particularly in the use of whole milk powder. Despite these warnings, Nara Organiсs continued to market its product, showcasing the high whole milk fat content as a selling point, while failing to adequately notify parents about the potential dangers.
Misleading Marketing
The central allegation in the lawsuit is that Nara Organics transformed its potentially hazardous high milk-powder content into a marketing strategy, presenting it as an attribute of premium quality, without any cautionary notes to consumers. After the outbreak, the company characterized its recall as a precautionary measure, carefully crafting its messaging to imply it was acting out of diligence rather than acknowledging its product's role in harming infants.
“Every company selling whole-milk-powder formula — including Nara — was explicitly warned about the contamination risk by spring 2026,” said Bill Marler, managing partner at Marler Clark. He highlighted that the company's messaging did not align with the known dangers, as they promoted their product as the safest on the market and failed to disclose the outlined risks.
The Impact on Families
The plaintiffs, Erica and Micky Goldfin, filed their lawsuit in the U.S. District Court for the Eastern District of Pennsylvania. Their son, identified in the case as W.G., exhibited clear signs of infant botulism just two months after starting on the formula. Initially showing symptoms typical of the illness, W.G. was treated at Children's Hospital of Philadelphia, where he spent crucial time under intensive care. While he has shown improvements, he continues to receive support for delays in development as a result of the illness.
Legislative Response
In light of the recent events, Bill Marler has responded with a call for Congress to pass the Infant Formula Safety Modernization Act, a bipartisan initiative introduced in March 2026. This proposed legislation would require infant formula manufacturers to engage in testing for Clostridium botulinum for the first time. Marler emphasized that such reforms could prevent further tragedies.
“This is a concrete step that could have averted this disaster. We must act now to ensure the safety of our children's food,” he urged.
Conclusion
The ongoing tragedy surrounding Nara Organics represents a lapse in accountability within the food industry and raises pressing concerns about the safety regulations governing infant feeding products. As investigations continue, the implications of this lawsuit serve as a stark reminder of the need for transparency and rigorous testing within the market. Parents trust manufacturers to provide safe products for their children, and cases like this highlight the urgent necessity for reform and more stringent oversight of food safety practices nationwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.